Halozyme Therapeutics (NASDAQ:HALO) Downgraded by Wall Street Zen to “Buy”

Wall Street Zen lowered shares of Halozyme Therapeutics (NASDAQ:HALO) from a strong-buy rating to a buy rating in a report published on Saturday,Wall Street Zen reports.

HALO has been the subject of a number of other reports. JPMorgan Chase & Co. increased their price target on Halozyme Therapeutics from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Tuesday, November 3rd. HC Wainwright lifted their price target on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. Stifel Nicolaus set a $130.00 price objective on Halozyme Therapeutics in a research note on Friday, October 16th. Finally, Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $83.00 to $110.00 in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $106.09.

Halozyme Therapeutics Trading Down 15.7%

NASDAQ:HALO opened at $103.63 on Friday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The firm has a market cap of $11.76 billion, a price-to-earnings ratio of 26.37, a price-to-earnings-growth ratio of 0.39 and a beta of 0.92. Halozyme Therapeutics has a 52 week low of $61.22 and a 52 week high of $134.00. The firm has a 50-day moving average price of $115.19 and a two-hundred day moving average price of $84.73.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the consensus estimate of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 488.26%. The firm had revenue of $492.97 million for the quarter, compared to analysts’ expectations of $491.63 million. During the same quarter last year, the firm earned $1.72 EPS. The company’s quarterly revenue was up 39.1% compared to the same quarter last year. On average, equities analysts expect that Halozyme Therapeutics will post 8.32 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew Posard sold 18,996 shares of the business’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total value of $2,046,629.04. Following the transaction, the director directly owned 58,839 shares in the company, valued at $6,339,313.86. The trade was a 24.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,852 shares of company stock worth $13,538,046 over the last three months. 2.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Horizon Investment Services LLC bought a new position in Halozyme Therapeutics in the 2nd quarter worth about $2,254,000. WINTON GROUP Ltd grew its holdings in Halozyme Therapeutics by 704.6% during the 2nd quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock valued at $4,723,000 after buying an additional 52,848 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $1,025,000. Great Lakes Advisors LLC purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $2,821,000. Finally, Chase Investment Counsel Corp bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at about $2,035,000. 97.79% of the stock is owned by institutional investors.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners.